JUMPCAN(SH:600566) Shang Hai Zheng Quan Bao·2025-08-22 23:41Group 1 - The company has established a wholly-owned subsidiary in Hainan with an investment of 100 million RMB and plans to set up a wholly-owned subsidiary in Hong Kong with an investment of 1 thousand HKD [3][6] - The new subsidiary in Hainan, named Jiajia (Hainan) Medical Technology Co., Ltd., will focus on drug clinical trial services, drug production, and medical services [6][7] - The investment is expected to leverage the policy benefits of the Hainan Free Trade Port and the geographical advantages of Hong Kong, enhancing the company's international market cooperation and overseas business expansion [9] Group 2 - The company reported a revenue of 8,016.89 million RMB and a net profit attributable to shareholders of 2,531.55 million RMB for the year 2024 [33] - The company emphasizes continuous cash dividends and shareholder returns, with a plan to repurchase shares using self-owned funds between 25 million and 50 million RMB [34][35] - The company has maintained a high-quality information disclosure standard, receiving an A-class rating for four consecutive years [36] Group 3 - The company has decided to cancel its supervisory board and amend its articles of association to enhance governance in accordance with the latest legal requirements [44][45] - The registered capital of the company has been adjusted from 9,218.0666 million RMB to 9,206.6066 million RMB due to the repurchase and cancellation of certain restricted stocks [43]